Difference between revisions of "Preoperative medication management"

From WikiAnesthesia
Tag: 2017 source edit
(Endocrine)
Line 49: Line 49:
=== Antiplatelets ===
=== Antiplatelets ===


== Endocrine ==
== Endocrine (Diabetes) ==
 
=== DPP-4 inhibitors (e.g. sitagliptin) ===
''Continue''
 
* No risk for hypoglycemia, though increased risk of gastric motility changes with continuation
 
=== Insulin ===
''Continue basal (long-acting) insulin and discontinue mealtime insulin, but assess on patient-by-patient basis''
 
* Discontinuing insulin increases risk of DKA, particularly in type 1 diabetics
* Continuing insulin increases risk for hypoglycemia, particularly when NPO
* Insulin pumps should remain on basal rate as well
* For long and/or complex surgeries, intraoperative glucose management may include IV insulin and dextrose infusions
 
=== Meglitinides (e.g. repaglinide) ===
''Discontinue day of surgery''
 
* Increased risk of hypoglycemia
 
=== Metformin ===
''Discontinue day of surgery''
 
* Increased risk of lactic acidosis
 
=== GLP-1 agonists (e.g. dulaglutide) ===
''Continue''
 
* No risk for hypoglycemia, though increased risk of gastric motility changes with continuation
 
=== SGLT2 inhibitors ===
''Discontinue 3-4 days before surgery''
 
* Increased risk of hypovolemia, AKI, and postoperative euglycemic DKA (elevated ketones, normal glucose)
 
=== Sulfonylureas (e.g. glipizide) ===
''Discontinue day of surgery''
 
* Increased risk of hypoglycemia
 
=== Thiazolidinediones (e.g. rosiglitazone) ===
''Discontinue day of surgery''
 
* Increased risk of hypervolemia (CHF, peripheral edema)
 
== Endocrine (Non-diabetes) ==


=== Glucocorticoids ===
=== Glucocorticoids ===
Line 86: Line 131:


* If continued, requires perioperative VTE prophylaxis
* If continued, requires perioperative VTE prophylaxis
=== Selective estrogen receptor modulators (SERMs) ===


== Pulmonary ==
== Pulmonary ==

Revision as of 07:23, 4 May 2021

Patients often have a long list of medications they take, and decisions must be made about whether to continue or hold them prior to surgery.

Cardiovascular

Beta blockers

Continue if taking chronically

  • Reduces coronary ischemia
  • Acute withdrawal of chronic beta blocker associated with increased morbidity/mortality

ACE inhibitors/Angiotensin receptor blockers (ARB)

Discontinue morning of surgery. However, could consider continuing for certain cardiac procedures on patient-by-patient basis

  • Inhibition of RAAS leads to refractory intraoperative hypotension
  • For most surgeries, appears to be no increase in mortality or cardiovascular events from holding ACE/ARB
    • However, some studies suggest myocardial protection in CABG

Diuretics

Discontinue morning of surgery if taking for hypertension and euvolemic

Continue if unstable volume status or history of poorly controlled heart failure

  • Theoretical risk of worsened hypotension due to intravascular depletion, though limited studies showing this in practice
  • Theoretical risk of hypokalemia, though this has not been observed in practice

Calcium channel blockers

Continue

  • Limited data showing neither benefit nor harm with continuation

Alpha 2 agonists (e.g. clonidine)

Continue if taking chronically

  • Prevent rebound hypertension

Digoxin

Continue

  • Limited data, though no evidence of adverse effects from continuation

Statins

Continue

  • Shown to prevent vascular events perioperatively

Heme

Anticoagulation

Antiplatelets

Endocrine (Diabetes)

DPP-4 inhibitors (e.g. sitagliptin)

Continue

  • No risk for hypoglycemia, though increased risk of gastric motility changes with continuation

Insulin

Continue basal (long-acting) insulin and discontinue mealtime insulin, but assess on patient-by-patient basis

  • Discontinuing insulin increases risk of DKA, particularly in type 1 diabetics
  • Continuing insulin increases risk for hypoglycemia, particularly when NPO
  • Insulin pumps should remain on basal rate as well
  • For long and/or complex surgeries, intraoperative glucose management may include IV insulin and dextrose infusions

Meglitinides (e.g. repaglinide)

Discontinue day of surgery

  • Increased risk of hypoglycemia

Metformin

Discontinue day of surgery

  • Increased risk of lactic acidosis

GLP-1 agonists (e.g. dulaglutide)

Continue

  • No risk for hypoglycemia, though increased risk of gastric motility changes with continuation

SGLT2 inhibitors

Discontinue 3-4 days before surgery

  • Increased risk of hypovolemia, AKI, and postoperative euglycemic DKA (elevated ketones, normal glucose)

Sulfonylureas (e.g. glipizide)

Discontinue day of surgery

  • Increased risk of hypoglycemia

Thiazolidinediones (e.g. rosiglitazone)

Discontinue day of surgery

  • Increased risk of hypervolemia (CHF, peripheral edema)

Endocrine (Non-diabetes)

Glucocorticoids

Continue, but consider stress dosing for patients on high-dose steroids or surgeries of long duration:

  • Stress dosing is indicated if daily dose (>3 weeks) is at least:
    • Dexamethasone 2 mg
    • Hydrocortisone 80 mg
    • Methylprednisolone 16 mg
    • Prednisone 20 mg
  • No stress dose is indicated if daily less less than:
    • Any dose of steroid taken for less than 3 weeks
    • Dexamethasone 0.5 mg
    • Hydrocortisone 20 mg
    • Methylprednisolone 4 mg
    • Prednisone 5 mg
  • For intermediate range, defer to patient history and HPA axis evaluation

If stress dose is indicated, hydrocortisone 300 mg/day (or equivalent) is common practice

Note: Avoid etomidate as an induction agent due to increased risk of adrenal crisis

Levothyroxine

Continue

  • To maintain euthyroid state
  • Can be given IM/IV at 80% dose if necessary

Methimazole/Propylthiouracil (PTU)

Continue

  • To maintain euthryoid state

Oral contraceptives (OCP)

Continue unless patient is has high risk of venous thromboembolism (VTE), in which case stop 4 weeks before surgery

  • If continued, requires perioperative VTE prophylaxis

Selective estrogen receptor modulators (SERMs)

Pulmonary

Beta agonists

Continue

  • Significant reduction in COPD/asthma complications

Anticholinergics

Continue

  • Significant reduction in COPD/asthma complications

Glucocorticoids (inhaled)

Continue

  • Avoids risk of adrenal insufficiency, particularly during stress of surgery
  • Inhaled dosage relatively low and unlikely to cause adverse events

Gastrointestinal (GI)

H2 blockers/Proton pump inhibitors (PPI)

Continue

  • Very safe intraoperatively
  • Prevents stress ulcers
  • Prevents gastric aspiration/chemical pneumonitis

Psych

Opioids

Other

Herbal supplements

References